

James W Murrough

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/615471/publications.pdf>

Version: 2024-02-01

151
papers

14,732
citations

25034

57
h-index

20358

116
g-index

162
all docs

162
docs citations

162
times ranked

13592
citing authors

#	ARTICLE	IF	CITATIONS
1	A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City. <i>International Archives of Occupational and Environmental Health</i> , 2022, 95, 1279-1291.	2.3	20
2	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. <i>Translational Psychiatry</i> , 2022, 12, 12.	4.8	14
3	The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants. <i>CNS Drugs</i> , 2022, 36, 207-216.	5.9	12
4	Association Between Depression and Severity of Dry Eye Symptoms, Signs, and Inflammatory Markers in the DREAM Study. <i>JAMA Ophthalmology</i> , 2022, 140, 392.	2.5	22
5	The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. <i>Journal of Affective Disorders</i> , 2022, , .	4.1	0
6	Beyond the neuron: Role of non-neuronal cells in stress disorders. <i>Neuron</i> , 2022, 110, 1116-1138.	8.1	18
7	Pharmacological Treatments for Anhedonia. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 467-489.	1.7	4
8	Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder. <i>Translational Psychiatry</i> , 2022, 12, 209.	4.8	12
9	Exaggerated amygdala response to threat and association with immune hyperactivity in depression. <i>Brain, Behavior, and Immunity</i> , 2022, 104, 205-212.	4.1	7
10	Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. <i>Molecular Psychiatry</i> , 2021, 26, 5140-5149.	7.9	59
11	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 383-391.	2.1	28
12	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 151-157.	4.3	6
13	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2021, 35, 124-127.	4.0	2
14	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , 2021, 178, 193-202.	7.2	122
15	Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls. <i>Frontiers in Psychiatry</i> , 2021, 12, 662963.	2.6	0
16	Transdiagnostic Psychiatric Symptoms, Burnout, and Functioning in Frontline Health Care Workers Responding to the COVID-19 Pandemic. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	15
17	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	7.2	270
18	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 437-446.	7.2	33

#	ARTICLE	IF	CITATIONS
19	Vortioxetine Versus Placebo for Major Depressive Disorder. Journal of Clinical Psychiatry, 2021, 82, .	2.2	16
20	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.8	9
21	Moral distress in frontline healthcare workers in the initial epicenter of the COVID-19 pandemic in the United States: Relationship to PTSD symptoms, burnout, and psychosocial functioning. Depression and Anxiety, 2021, 38, 1007-1017.	4.1	86
22	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology, 2021, 46, 2266-2277.	5.4	19
23	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depression and Anxiety, 2021, 38, 1108-1119.	4.1	6
24	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. Journal of Medical Internet Research, 2021, 23, e31295.	4.3	15
25	Psychological Impact of the COVID-19 Pandemic on Frontline Health Care Workers During the Pandemic Surge in New York City. Chronic Stress, 2021, 5, 247054702097789.	3.4	65
26	Intrasubject functional connectivity related to self-generated thoughts. Brain and Behavior, 2021, 11, e01860.	2.2	2
27	Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. Translational Psychiatry, 2021, 11, 565.	4.8	27
28	Effects of Sleep, Exercise, and Leadership Support on Resilience in Frontline Healthcare Workers During the COVID-19 Pandemic. Journal of Occupational and Environmental Medicine, 2021, Publish Ahead of Print, .	1.7	3
29	Chemical, Manufacturing, and Standardization Controls of Grape Polyphenol Dietary Supplements in Support of a Clinical Study: Mass Uniformity, Polyphenol Dosage, and Profiles. Frontiers in Nutrition, 2021, 8, 780226.	3.7	1
30	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	7.9	235
31	Effects of chronic physical disease and systemic inflammation on suicide risk in patients with depression: a hospital-based case-control study. Psychological Medicine, 2020, 50, 29-37.	4.5	20
32	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Molecular Psychiatry, 2020, 25, 1323-1333.	7.9	40
33	Shared Neural Phenotypes for Mood and Anxiety Disorders. JAMA Psychiatry, 2020, 77, 172.	11.0	106
34	Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. World Journal of Biological Psychiatry, 2020, 21, 696-710.	2.6	34
35	Neural correlates of rumination in major depressive disorder: A brain network analysis. NeuroImage: Clinical, 2020, 25, 102142.	2.7	62
36	Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Australian and New Zealand Journal of Psychiatry, 2020, 54, 29-45.	2.3	126

#	ARTICLE	IF	CITATIONS
37	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 783-790.	2.1	23
38	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , 2020, 266, 615-620.	4.1	28
39	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , 2020, 11, 595584.	2.6	143
40	The role of the locus coeruleus in the generation of pathological anxiety. <i>Brain and Neuroscience Advances</i> , 2020, 4, 239821282093032.	3.4	102
41	Dissociating self-generated volition from externally-generated motivation. <i>PLoS ONE</i> , 2020, 15, e0232949.	2.5	6
42	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020, 45, 1656-1663.	5.4	50
43	Pharmacological Treatments for Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2020, 13, 116.	3.8	78
44	A randomized proof-of-mechanism trial applying the “fast-fail” approach to evaluating μ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020, 26, 760-768.	30.7	129
45	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. <i>Advances in Pharmacology</i> , 2020, 89, 163-194.	2.0	8
46	Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivo Ultra-high field 7-Tesla MRI study. <i>NeuroImage: Clinical</i> , 2020, 25, 102148.	2.7	25
47	Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. <i>Neuropsychopharmacology</i> , 2020, 45, 975-981.	5.4	71
48	Efficacy of Esketamine Augmentation in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	71
49	High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. <i>Neuropsychopharmacology</i> , 2019, 44, 390-398.	5.4	19
50	Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. <i>Patient</i> , 2019, 12, 527-537.	2.7	9
51	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1140, 585-600.	1.6	5
52	116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective μ -Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. <i>Biological Psychiatry</i> , 2019, 85, S48-S49.	1.3	0
53	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , 2019, 3, 247054701987788.	3.4	2
54	The Neurobiology of Resilience: Complexity and Hope. <i>Biological Psychiatry</i> , 2019, 86, 406-409.	1.3	17

#	ARTICLE	IF	CITATIONS
55	132. Structural and Connectomic Brain Features of Treatment Resistant Depression and Antidepressant Response to Ketamine. <i>Biological Psychiatry</i> , 2019, 85, S55.	1.3	0
56	S8. Increased Locus Coeruleus Volume in Humans With Pathological Anxiety: An Ultra-High Field 7-Tesla MRI Study. <i>Biological Psychiatry</i> , 2019, 85, S299-S300.	1.3	0
57	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , 2019, 44, 1233-1238.	5.4	35
58	Neurobiology of Resilience: Interface Between Mind and Body. <i>Biological Psychiatry</i> , 2019, 86, 410-420.	1.3	175
59	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2019, 44, 1812-1819.	5.4	32
60	Screening and Management of Depression in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1827-1845.	2.8	182
61	Hippocampal subfield-specific connectivity findings in major depressive disorder: A 7 Tesla diffusion MRI study. <i>Journal of Psychiatric Research</i> , 2019, 111, 186-192.	3.1	14
62	Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla. <i>Translational Psychiatry</i> , 2019, 9, 94.	4.8	37
63	F124. Mapping the Neural Correlates of Mood and Anxiety Disorders Onto Research Domain Criteria: A Meta-Analysis of 226 Task-Related Functional Imaging Studies. <i>Biological Psychiatry</i> , 2019, 85, S261.	1.3	3
64	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. <i>Focus (American Journal of Psychiatry)</i> , 2019, 117, 1038-1044.	0.8	1
65	Electroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. <i>Contemporary Clinical Trials</i> , 2019, 77, 19-26.	1.8	34
66	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 82-84.	46.4	52
67	Determinants and Predictive Value of Clinician Assessment of Short-Term Suicide Risk. <i>Suicide and Life-Threatening Behavior</i> , 2019, 49, 614-626.	1.9	30
68	New Mechanisms, New Opportunities. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	0
69	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , 2018, 230, 56-64.	4.1	36
70	T131. KNCQ Channel Opener Ezogabine_x000B_as a Treatment for Depression: A Preliminary Resting State fMRI Analysis. <i>Biological Psychiatry</i> , 2018, 83, S179.	1.3	0
71	86. Role of the Epigenetic Agent Acetyl-L-Carnitine as Gating Biomarker in Depression and Influences of Childhood Trauma. <i>Biological Psychiatry</i> , 2018, 83, S35-S36.	1.3	0
72	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , 2018, 175, 150-158.	7.2	476

#	ARTICLE	IF	CITATIONS
73	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018, 11, 75-84.	1.6	20
74	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	4.8	26
75	F142. Effect of Treatment Resistance Status on Whole Brain Voxel-Based Morphometry in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2018, 83, S293.	1.3	0
76	F163. Inflammation is Associated With Mesolimbic Reward Circuitry in Major Depression. <i>Biological Psychiatry</i> , 2018, 83, S302.	1.3	0
77	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , 2018, 1, .	10.9	16
78	Acetyl- L -carnitine deficiency in patients with major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8627-8632.	7.1	102
79	T129. Brain Connectivity Changes Associated With a Cognitive-Emotional Training Intervention for Depression. <i>Biological Psychiatry</i> , 2018, 83, S178.	1.3	0
80	65. From Stress Resilience to Novel Therapeutics: KCNQ Channel Openers and Other Approaches Emerging From Translational Neuroscience. <i>Biological Psychiatry</i> , 2018, 83, S27.	1.3	0
81	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 3-11.	2.1	56
82	Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. <i>Lancet, The</i> , 2017, 389, 834-845.	13.7	442
83	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , 2017, 218, 277-283.	4.1	41
84	Neuropeptide Y, resilience, and PTSD therapeutics. <i>Neuroscience Letters</i> , 2017, 649, 164-169.	2.1	62
85	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. <i>Translational Psychiatry</i> , 2017, 7, e1065-e1065.	4.8	135
86	Targeting glutamate signalling in depression: progress and prospects. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 472-486.	46.4	345
87	Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. <i>Human Brain Mapping</i> , 2017, 38, 6068-6082.	3.6	63
88	171. A Randomized Controlled Dose-Ranging Study of Intranasal Administration of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 81, S71.	1.3	1
89	871. Modulation of the Insula and Somatosensory Cortex by Ondansetron. <i>Biological Psychiatry</i> , 2017, 81, S352.	1.3	0
90	Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?. <i>Biological Psychiatry</i> , 2017, 82, 858-860.	1.3	13

#	ARTICLE	IF	CITATIONS
91	Prazosin during threat discrimination boosts memory of the safe stimulus. <i>Learning and Memory</i> , 2017, 24, 597-601.	1.3	12
92	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , 2017, 42, 1210-1219.	5.4	240
93	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , 2016, 37, 3214-3223.	3.6	125
94	Ketamine for treatment-resistant depression: recent developments and clinical applications: Table 1. <i>Evidence-Based Mental Health</i> , 2016, 19, 35-38.	4.5	102
95	Ketamine's Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies. , 2016, , 99-121.		1
96	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 816-826.	7.2	388
97	Ketamine for Depression: An Update. <i>Biological Psychiatry</i> , 2016, 80, 416-418.	1.3	17
98	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. <i>Nature Communications</i> , 2016, 7, 11671.	12.8	109
99	Cortical abnormalities and association with symptom dimensions across the depressive spectrum. <i>Journal of Affective Disorders</i> , 2016, 190, 529-536.	4.1	38
100	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. <i>Psychological Medicine</i> , 2015, 45, 3571-3580.	4.5	244
101	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. <i>Neuropsychopharmacology</i> , 2015, 40, 1084-1090.	5.4	117
102	Ketamine for Posttraumatic Stress Disorder—Reply. <i>JAMA Psychiatry</i> , 2015, 72, 95.	11.0	6
103	Emerging drugs for the treatment of anxiety. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 393-406.	2.4	102
104	“Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?” Current Treatment Options in Psychiatry, 2015, 2, 383-393.	1.9	5
105	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 216-225.	1.3	18
106	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 47-58.	3.8	70
107	Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations. <i>Psychopharmacology</i> , 2015, 232, 1497-1499.	3.1	1
108	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , 2015, 5, e509-e509.	4.8	93

#	ARTICLE	IF	CITATIONS
109	Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2015, 76, 247-252.	2.2	179
110	Cerebellar Morphology and the Effects of Stimulant Medications in Youths with Attention Deficit-Hyperactivity Disorder. Neuropsychopharmacology, 2014, 39, 718-726.	5.4	59
111	Advances in Psychopharmacology for Anxiety Disorders. Focus (American Psychiatric Publishing), 2014, 12, 152-162.	0.8	13
112	COGNITIVE-EMOTIONAL TRAINING AS AN INTERVENTION FOR MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2014, 31, 699-706.	4.1	58
113	EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION. Depression and Anxiety, 2014, 31, 335-343.	4.1	275
114	Attention Bias Variability and Symptoms of Posttraumatic Stress Disorder. Journal of Traumatic Stress, 2014, 27, 232-239.	1.8	145
115	Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. JAMA Psychiatry, 2014, 71, 681.	11.0	466
116	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology, 2014, 231, 481-488.	3.1	73
117	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16136-16141.	7.1	545
118	Current Treatments for Anxiety and Obsessive-Compulsive Disorders. Current Treatment Options in Psychiatry, 2014, 1, 248-262.	1.9	2
119	In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neuroscience Letters, 2014, 569, 74-79.	2.1	45
120	A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biological Psychiatry, 2014, 76, 970-976.	1.3	369
121	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology, 2014, 17, 331-336.	2.1	195
122	Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. Biological Psychiatry, 2013, 74, 250-256.	1.3	632
123	Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. American Journal of Psychiatry, 2013, 170, 1134-1142.	7.2	965
124	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatric Disease and Treatment, 2013, 9, 1101.	2.2	76
125	Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs, 2012, 26, 189-204.	5.9	203
126	Is There Anything Really Novel on the Antidepressant Horizon?. Current Psychiatry Reports, 2012, 14, 643-649.	4.5	59

#	ARTICLE	IF	CITATIONS
127	Neurobiology of resilience. Nature Neuroscience, 2012, 15, 1475-1484.	14.8	934
128	Positron Emission Tomography Shows Elevated Cannabinoid CB_1 Receptor Binding in Men with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2012, 36, 2104-2109.	2.4	53
129	CHAPTER 9. Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder. RSC Drug Discovery Series, 2012, , 226-257.	0.3	0
130	Ketamine as a Novel Antidepressant: From Synapse to Behavior. Clinical Pharmacology and Therapeutics, 2012, 91, 303-309.	4.7	147
131	ECT in Treatment-Resistant Depression. American Journal of Psychiatry, 2012, 169, 1238-1244.	7.2	208
132	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR in Biomedicine, 2012, 25, 1073-1087.	2.8	134
133	The Serotonin Transporter and Emotionality: Risk, Resilience, and New Therapeutic Opportunities. Biological Psychiatry, 2011, 69, 510-512.	1.3	19
134	Reply to: Dose- and Exposure-Response to Ketamine in Depression. Biological Psychiatry, 2011, 70, e11-e12.	1.3	6
135	The Serotonin 1B Receptor: A New Target for Depression Therapeutics?. Biological Psychiatry, 2011, 69, 714-715.	1.3	15
136	Reduced Amygdala Serotonin Transporter Binding in Posttraumatic Stress Disorder. Biological Psychiatry, 2011, 70, 1033-1038.	1.3	79
137	Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. Neurobiology of Learning and Memory, 2011, 96, 553-563.	1.9	264
138	A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology, 2011, 21, 221-229.	0.7	44
139	Reduced ventral striatal/ventral pallidal serotonin $1B$ receptor binding potential in major depressive disorder. Psychopharmacology, 2011, 213, 547-553.	3.1	118
140	The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand Binding. Archives of General Psychiatry, 2011, 68, 892.	12.3	84
141	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. Psychiatric Annals, 2011, 41, 408-412.	0.1	4
142	A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2011, 72, 414-415.	2.2	37
143	Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR in Biomedicine, 2010, 23, 643-650.	2.8	68
144	Cracking the moody brain: Lifting the mood with ketamine. Nature Medicine, 2010, 16, 1384-1385.	30.7	31

#	ARTICLE	IF	CITATIONS
145	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology, 2010, 13, 71-82.	2.1	239
146	Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. Biological Psychiatry, 2010, 67, 139-145.	1.3	589
147	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. Modern Problems of Pharmacopsychiatry, 2010, , 89-100.	2.5	1
148	Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder. Biological Psychiatry, 2009, 65, 792-800.	1.3	227
149	A Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder. Biological Psychiatry, 2009, 66, 656-664.	1.3	209
150	Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal Subjects. American Journal of Psychiatry, 2006, 163, 1784-1790.	7.2	424
151	Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage. Brain Research, 2000, 883, 125-130.	2.2	8